T1	Participants 944 1012	153 anemic cancer patients receiving cyclic combination chemotherapy
T2	Participants 1087 1095	patients
T3	Participants 2265 2289	placebo-treated patients
T4	Participants 2337 2360	rHuEPO-treated patients
T5	Participants 1734 1754	rHuEPO-treated group
